June 17, 2021 7:39am

As the cell and gene therapy sector runs out of buyers, it runs into trouble (just like a fire that runs out of wood)

Pre-open indications: 2 SELLs: CRSP and EDIT; 1 Maintain SELL: BSTG

My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! 

 

Dow futures are DOWN -0.17% (-57 points), S&P futures are DOWN -0.18% (-8 point) and NASDAQ futures are DOWN -0.29% (-40 points)

 

U.S. stock futures are down in early pre-market on Thursday,

European stocks were down with the pan-European Stoxx 600 fell 0.4% by late morning,

Asia-Pacific stocks mostly pulled back

 

Data Docket: Weekly jobless claims and the Philadelphia Fed business outlook

 

Henry’omics:

Remember that pre-market action in futures and doesn't necessarily translate into actual trading in the up-coming stock market session.

Yesterday, Fed chair Powell also did NOT issue guidance on when the central bank will begin tapering its bond-buying program; but he did say the central bank will continue to monitor the economic recovery and will provide “advanced notice” before announcing any updates regarding tapering.

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (32 – MESO added) to date …  https://www.regmedinvestors.com/articles/11628

 

Wednesday’s evening’s recap: “as expected, gravity induced by the Fed was a sector force” … https://www.regmedinvestors.com/articles/11958

  • The Nasdaq closed DOWN -33.17 points (-0.24%);
  • The IBB closed down -0.72% and XBI closed up +0.12%;
  • Sector volume was LOW with 3 of the 10-upside having higher than the 3-month average volume with the volume of 6 of 22-downside having higher than the 3-month average volume;
  • The CBOE Volatility Index (VVIX: INDEX) was up +1.13points or +6.64% at 18.15;
  • Wednesday’s percentage (%) of the 10-upside were +0.08% (BLFS) to +7.43% (BSTG) while the 22-downside ranges from -0.06% (QURE) to -10.61% (NTLA);

Q2/21:

June: 7 positive and 4 negative closes

May:  8 positive, 12 negative closes and 1 holiday

April: 11 negative and 10 positive closes

Q1/21:

  • March: 10 positive, 12 negative and 1 neutral closes
  • February: 9 positive, 10 negative closes and 1 holiday
  • January: 10 positive, 9 negative closes and 1 holiday

 

Companies in my headlights – It’s your decision; I provide an idea and context:

The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …

Biostage (BSTG) closed up +$0.089 to $1.30 with 205 shares traded after Tuesday’s -$0.039 to $1.21 with 10,703 shares traded after Monday’s flat at $1.25 with 2,305 shares traded, Friday’s +$0.04 with 1,395 shares traded to $1.25, Thursday’s +$0.01 to $1.21 with 1,325 shares traded and Wednesday’s +$0.13 to $1.26 with 1,216 shares traded. WHO is trading this ZOMBIE or PIG?

Question#`1: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?

Question#2: Will the annual meeting result in ANY news to/about the future of the company?

Question#3: WHY do I keep writing on BSTG – I was there and then SUDDENLY I wasn’t (there through NO fault of my own other than to UPHOLD the law) and saw WHAT they DID, WERE, KEPT on doing and CONTINUE to do - but, the REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors?

MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.

 

The morning’s indications:

SELL:

CRISPR Therapeutics (CRSP) closed up +$0.29 to $123.91 and has a negative -$1.91 or -1.54% pre-market indication.

Editas Medicine (EDIT) closed down -$0.10 to $35.00 after Tuesday’s -$3.43 to $35.19 and has a negative indication of -$0.65 or -1.86%

 

The BOTTOM LINE: Not much has changed for me to “spout” … Wake-up volatility is NOT going away!

I continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored.

When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started

Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”

A true contrarian thought …

My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.

My motto, never leave an investor uninformed about what I know!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.